MAURICE HARDGROVE; IRVING L. APPLEBAUM, F.A.C.P.
Plasmochin has had a checkered career in the rôle of an anti-malarial agent since it was first introduced into clinical medicine by Mühlens1 in 1926. The literature is abundant with references which approximate 400 monographs and articles, but it is not within the scope of this paper to present a historical review. Although plasmochin was initially given a trial as the sole anti-malarial drug in various types of the disease, its usage gradually became limited. It has been employed for primary attacks of malaria in combination with quinine and atabrine; in blackwater fever when sensitivity to quinine was suspected; in
HARDGROVE M, APPLEBAUM IL. PLASMOCHIN TOXICITY: ANALYSIS OF 258 CASES1. Ann Intern Med. ;25:103–112. doi: 10.7326/0003-4819-25-1-103
Download citation file:
Published: Ann Intern Med. 1946;25(1):103-112.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use